Included under terms of UK Non-commercial Government License.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Headline
Study finds that there is still insufficient evidence to advocate a clear benefit of the addition of anti-platelet therapy to anticoagulant therapy, compared with anticoagulant therapy alone, in reducing the risk of vascular events in a population of patients who are at high risk of thromboembolic events resulting from atrial fibrillation
Abstract
Background:
Previous research suggests uncertainty whether or not there is any additional benefit in adding antiplatelet therapy (APT) to anticoagulation therapy (ACT) in patients with high-risk atrial fibrillation (AF) in terms of reduction in vascular events, including stroke. The existing guidelines acknowledge an increased risk of bleeding associated with such a strategy; however, there is no consensus on the treatment pathway.
Objectives:
To determine, by undertaking a systematic review, if the addition of APT to ACT is beneficial compared with ACT alone in patients with AF who are considered to be at high risk of thromboembolic events (TEs).
Data sources:
Data sources included bibliographic databases {the Cochrane Library [Cochrane Central Register of Controlled Trials (CENTRAL)], MEDLINE, MEDLINE In-Process and Other Non-Indexed Citations, EMBASE, ClinicalTrials.gov, National Institute for Health Research (NIHR) Clinical Research Network Portfolio, Current Controlled Trials (CCT) and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP)}, reference lists from identified systematic reviews and relevant studies, and contact with clinical experts. Searches were from inception to September 2010 and did not use language restrictions or study design filters.
Review methods:
Studies of any design were included to evaluate clinical effectiveness, including randomised controlled trials (RCTs), non-randomised comparisons, cohort studies, case series or registries, longitudinal studies, systematic reviews and meta-analyses, and conference abstracts published after 2008. Inclusion criteria consisted of a population with AF, at high-risk of TEs, aged ≥ 18 years, on combined ACT and APT compared with others on ACT alone or ACT plus placebo. Inclusion decisions, assessment of study quality and data extraction were undertaken using methods to minimise bias.
Results:
Fifty-three publications were included, reporting five RCTs (11 publications), 18 non-randomised comparisons (24 publications) and 18 publications that reported reviews, which added no further data. There was variation in the population, types and doses of ACT and APT, definitions of outcomes, and length of follow-up between the studies. There was a paucity of directly randomised high-quality RCTs, whereas non-randomised comparisons were found to have significant confounding factors. No studies looked at the effect of ACT plus APT compared with ACT alone on vascular events in patients with AF following acute coronary syndrome (ACS) or percutaneous coronary intervention. In most studies, significant differences in event rates were not seen between the patients on combined therapy compared with those on ACT alone for outcomes such as stroke (including haemorrhagic and ischaemic strokes), rates of transient ischaemic attacks, composite end points of stroke and systemic embolism (SE), SE alone, acute myocardial infarction, mortality (vascular or all cause) or bleeding events. There was conflicting evidence regarding rates of major adverse events consisting of composite end points, although event rates were generally low.
Limitations:
An attempt was made to identify all of the available evidence around the subject despite the dearth of directly randomised studies using a robust review methodology. There was a paucity of directly randomised evidence to undertake a meta-analysis for the merits of one technology over another. The selection criteria were kept necessarily broad with regard to the population, intervention and comparator in order to capture all relevant studies.
Conclusions:
This systematic review suggests that there is still insufficient evidence to advocate a clear benefit of the addition of APT to ACT compared with ACT alone in reducing the risk of vascular events in a population of patients at high risk of TEs resulting from AF. It is recommended that a definitive prospective RCT needs to be undertaken in a population at high risk of atherosclerotic coronary artery and other vascular events in addition to being at high risk of AF-mediated TEs. From the UK context, at the time of writing, any future trial should compare adjusted-dose warfarin [international normalised ratio (INR) 2.0–3.0] plus aspirin (75–325 mg) with adjusted-dose warfarin (INR 2.0–3.0). However, given the emergence of newer anticoagulation agents (dabigatran, rivaroxaban and apixaban) this prioritisation may need to be revisited in the future to reflect current best clinical practice.
Funding:
The National Institute for Health Research Health Technology Assessment programme.
Contents
- Scientific summary
- Chapter 1. Background
- Chapter 2. Methods
- Chapter 3. Results
- Chapter 4. Discussion
- Acknowledgements
- References
- Appendix 1 Final protocol
- Appendix 2 Literature search strategies
- Appendix 3 Publications not available after contacting authors
- Appendix 4 List of excluded studies
- Appendix 5 Summary of the systematic reviews and meta-analyses included in the review
- Appendix 6 Quality assessment of randomised comparisons using the Cochrane Collaboration risk-of-bias tools
- Appendix 7 Studies with data not included in the review and reasons
- Appendix 8 Forest plots (without summary estimates) for all outcomes by intervention and comparator
- Glossary
- List of abbreviations
Article history paragraph text
The research reported in this issue of the journal was funded by the HTA programme as project number 09/11/02. The contractual start date was in June 2010. The draft report began editorial review in January 2012 and was accepted for publication in September 2012. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.
Declared competing interests of authors
DAL has received an investigator-initiated educational grant from Bayer Healthcare and honoraria from Boehringer Ingelheim, Bayer HealthCare, Bristol-Myers Squibb, Sanofi-aventis and Pfizer. In addition, DAL is a panellist on the ninth edition of the American College of Chest Physicians guidelines on antithrombotic therapy in atrial fibrillation. DAF has received honoraria from Boehringer Ingelheim, Sanofi-aventis, and AstraZeneca
- Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.[Cochrane Database Syst Rev. 2020]Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.Bala MM, Celinska-Lowenhoff M, Szot W, Padjas A, Kaczmarczyk M, Swierz MJ, Undas A. Cochrane Database Syst Rev. 2020 Oct 12; 10(10):CD012169. Epub 2020 Oct 12.
- Review Antiplatelet agents and anticoagulants for hypertension.[Cochrane Database Syst Rev. 2011]Review Antiplatelet agents and anticoagulants for hypertension.Lip GY, Felmeden DC, Dwivedi G. Cochrane Database Syst Rev. 2011 Dec 7; 2011(12):CD003186. Epub 2011 Dec 7.
- Review Antithrombotic treatment after stroke due to intracerebral haemorrhage.[Cochrane Database Syst Rev. 2023]Review Antithrombotic treatment after stroke due to intracerebral haemorrhage.Cochrane A, Chen C, Stephen J, Rønning OM, Anderson CS, Hankey GJ, Al-Shahi Salman R. Cochrane Database Syst Rev. 2023 Jan 26; 1(1):CD012144. Epub 2023 Jan 26.
- Review Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.[Health Technol Assess. 2017]Review Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.Sterne JA, Bodalia PN, Bryden PA, Davies PA, López-López JA, Okoli GN, Thom HH, Caldwell DM, Dias S, Eaton D, et al. Health Technol Assess. 2017 Mar; 21(9):1-386.
- Review Antiplatelet and anticoagulation for patients with prosthetic heart valves.[Cochrane Database Syst Rev. 2013]Review Antiplatelet and anticoagulation for patients with prosthetic heart valves.Massel DR, Little SH. Cochrane Database Syst Rev. 2013 Jul 9; 2013(7):CD003464. Epub 2013 Jul 9.
- Combined anticoagulation and antiplatelet therapy for high-risk patients with at...Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review
Your browsing activity is empty.
Activity recording is turned off.
See more...